Innovent Biologics IBI343 (CLDN 18.2 antibody drug conjugate) completed the dosing of the first subject in Australia
Time of Update: 2022-11-04
62em; font-family:"Arial"; color:black; margin:0in; } ROCKVILLE, USA and Suzhou, China, Oct. 31, 2022 /PRNewswire/ -- Innovent Biopharmaceutical Group (HKEx: 01801), a biopharmaceutical company dedicated to the development, production and sale of innovative drugs for major diseases such as oncology, autoimmunity, metabolism and ophthalmology, today announced its recombinant human anti-tight connexin 18.
Youyoung Good Medical Voice Plan the overall situation, make accurate decisions, and how to "step by step" the whole process management of advanced colorectal cancer patients
Time of Update: 2022-11-04
*Only for medical professionals to read and refer to "Youyoung Good Medical Voice" Shanghai-Fujian-Gan Station wonderful case sharing is coming! On September 4, 2022, the Chinese Society of Clinical O
After the new crown, the next arena for mRNA vaccines
Time of Update: 2022-11-01
Exclusive Original | Challenges and prospects of mRNA oncology vaccine development; Advances in Pharmacy In order to survive, the tumor staged "infernal affairs" in the battle with the immune system.
Mitochondria Mic60 and cancer
Time of Update: 2022-10-20
"To our knowledge, this is the first time that genetic signatures of mitochondrial dysfunction have been found to be associated with aggressive cancer subtypes, treatment resistance, and unfortunately low patient survival.
The pivotal Phase 3 clinical results of IL-2 receptor targeted therapy are positive, and the marketing application is expected to be submitted this year
Time of Update: 2022-04-17
Today, Citius Pharmaceuticals announced positive top-line results from a pivotal Phase 3 clinical trial of its investigational therapy I/ONTAK (E7777) in patients with persistent or relapsed cutaneous T-cell lymphoma (CTCL) .
Adv Mater biomimetic lipoprotein system remodels tumor physical barrier and enhances T cell infiltration
Time of Update: 2022-03-09
Figure 1 S-LFO remodels the tumor stromal barrier and promotes T cell infiltrationFigure 2 S-LFO promotes intratumoral infiltration of CTLs Researcher Zhang Zhiwen and Li Yaping from Shanghai Institute of Materia Medica and Professor Wang Siling from Shenyang Pharmaceutical University are the co-corresponding authors of this article.
New approach to targeting mutated RAS offers hope for cancer patients
Time of Update: 2022-03-07
Because the R15 monomer does not easily enter cells, O'bryan explained that a small molecule targeting the nucleotide-free mutant RAS protein would be a more effective treatment .
Molecular Cancer Zhang Hao's team from Jinan University found that saliva-derived exosomal small RNAs can be used as biomarkers for the diagnosis and prognosis of esophageal cancer
Time of Update: 2022-02-22
This study identified cancer-enriched small RNAs by RNA sequencing of salivary exosomes obtained from esophageal squamous cell carcinoma (ESCC) patients (n = 3) and healthy controls (n = 3).
Nature: Philadelphia Children's Hospital has developed a new CAR T cell therapy
Time of Update: 2021-11-13
Despite these problems, researchers at the Children's Hospital of Philadelphia hypothesized that some peptides on the cell surface of neuroblastoma are derived from proteins that are essential for tumor growth and survival and can be targeted by synthetic CARs .
Eur J Cancer: More than half of patients treated with dabrafenib combined with trametinib will experience fever
Time of Update: 2021-08-01
1% of patients had recurrent fever 3 times or moreIn summary, fever is the most common adverse event in treatment with dabrafenib combined with trametinib.
Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers .
Br J Cancer: Migrastatic: Potential anti-metastatic therapy for metastatic melanoma
Time of Update: 2021-07-31
And through in vitro target verification, a new type of traceable spontaneous metastatic melanoma model was developed for in vivo verification, and the drug effect of tumor tissue was confirmed through histological experiments .
Transcription factors protect anti-cancer CAR-T cells from depletion
Time of Update: 2021-07-27
. The latest research results show that the transcription factor BATF plays a key role in the cellular pathway that triggers T cell failure, and shows how the increase in BATF levels with the help of another transcription factor IRF4 can improve the anti-cancer ability of these cells .
BeiGene will announce a number of clinical and preclinical data at the 2021 annual meeting of the American Association for Cancer Research
Time of Update: 2021-07-19
BeiGene is a commercial biotechnology company focusing on the development and commercialization of innovative drugs on a global scale .
Bluestar Genomics' early screening test was recognized by the FDA as a breakthrough medical device
Time of Update: 2021-04-19
One of the reasons why it is difficult to treat is that the symptoms of early pancreatic cancer are mild, and most patients are already at an advanced stage when they are diagnosed.
The incidence of skin cancer reaches 45% within 10 years
Time of Update: 2021-02-15
The figures have been released to mark the charity's own rhythmic event, which encourages people to embrace natural skin tones and protect them from the sun.
Tanning every two years triples the risk of melanoma skin cancer.